Revenue Growth, Losses

Medincell's FY 2025-26 financials reflect a year of solid execution and transition towards multiple commercialized innovative products based on its technology. The company generated €24.3 million in total revenues, with UZEDY royalties contributing €9.3 million, confirming the evolution of the revenue model. Operating expenses increased by 17% year-over-year to support pipeline expansion and long-term value creation, resulting in an operating loss of €20.8 million.